Murine Oncostatin M Has Opposing Effects on the Proliferation of OP9 Bone Marrow Stromal Cells and NIH/3T3 Fibroblasts Signaling through the OSMR

The IL-6 family cytokine Oncostatin M (OSM) is involved in cell development, growth, hematopoiesis, inflammation, and cancer. Intriguingly, OSM has proliferative and antiproliferative effects depending on the target cell. The molecular mechanisms underlying these opposing effects are not fully understood. Previously, we found OSM upregulation in different myeloproliferative syndromes. However, OSM receptor (OSMR) expression was detected on stromal cells but not the malignant cells themselves. In the present study, we, therefore, investigated the effect of murine OSM (mOSM) on proliferation in stromal and fibroblast cell lines. We found that mOSM impairs the proliferation of bone marrow (BM) stromal cells, whereas fibroblasts responded to mOSM with increased proliferation. When we set out to reveal the mechanisms underlying these opposing effects, we detected increased expression of the OSM receptors OSMR and LIFR in stromal cells. Interestingly, Osmr knockdown and Lifr overexpression attenuated the OSM-mediated effect on proliferation in both cell lines indicating that mOSM affected the proliferation signaling mainly through the OSMR. Furthermore, mOSM induced activation of the JAK-STAT, PI3K-AKT, and MAPK-ERK pathways in OP9 and NIH/3T3 cells with differences in total protein levels between the two cell lines. Our findings offer new insights into the regulation of proliferation by mOSM.

[1]  G. Müller-Newen,et al.  Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization , 2021, Leukemia.

[2]  André F. Rendeiro,et al.  STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway , 2020, Oncogene.

[3]  A. Zekiy,et al.  Oncostatin M: A mysterious cytokine in cancers. , 2020, International immunopharmacology.

[4]  F. Tang,et al.  Single-Cell Multiomics Sequencing Reveals Prevalent Genomic Alterations in Tumor Stromal Cells of Human Colorectal Cancer. , 2020, Cancer cell.

[5]  R. Moriggl,et al.  Targeting STAT3 and STAT5 in Cancer , 2020, Cancers.

[6]  Hao Wang,et al.  Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways , 2020, Experimental physiology.

[7]  M. Mohty,et al.  Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. , 2020, The New England journal of medicine.

[8]  A. J. Thompson,et al.  Evidence for an effect of receptor density on ligand occupancy and agonist EC50 , 2019, Scientific Reports.

[9]  C. Drake,et al.  A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth. , 2019, Cell stem cell.

[10]  Alireza Hadj Khodabakhshi,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[11]  Zhenghui Liu,et al.  Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin-dependent inflammation and thrombosis. , 2019, Blood advances.

[12]  Judith A. Blake,et al.  Mouse Genome Database (MGD) 2019 , 2018, Nucleic Acids Res..

[13]  R. Majeti,et al.  Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis , 2018, Science Advances.

[14]  P. Denormandie,et al.  Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications. , 2017, JCI insight.

[15]  R. Owens,et al.  Oncostatin M drives intestinal inflammation in mice and its abundance predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease , 2017, Nature Medicine.

[16]  G. Smyth,et al.  Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass* , 2016, The Journal of Biological Chemistry.

[17]  S. Rose-John,et al.  The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth , 2016, Oncotarget.

[18]  L. Hennighausen,et al.  Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3+-mediated leukemic phenotype , 2016, Leukemia.

[19]  R. Oostendorp,et al.  Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression , 2016, The Journal of experimental medicine.

[20]  W. Lee,et al.  Adiponectin Induces Oncostatin M Expression in Osteoblasts through the PI3K/Akt Signaling Pathway , 2015, International journal of molecular sciences.

[21]  A. Christiano,et al.  Pharmacologic inhibition of JAK-STAT signaling promotes hair growth , 2015, Science Advances.

[22]  D. Smyth,et al.  Oncostatin M regulates osteogenic differentiation of murine adipose-derived mesenchymal progenitor cells through a PKCdelta-dependent mechanism , 2015, Cell and Tissue Research.

[23]  M. Griesshammer,et al.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera. , 2015, The New England journal of medicine.

[24]  J. Prados,et al.  Serum Cytokine Profile in Patients With Pancreatic Cancer , 2014, Pancreas.

[25]  P. Watson,et al.  Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer , 2014, Oncogene.

[26]  X. Chen,et al.  Stat3-coordinated Lin-28–let-7–HMGA2 and miR-200–ZEB1 circuits initiate and maintain oncostatin M-driven epithelial–mesenchymal transition , 2013, Oncogene.

[27]  B. Trigatti,et al.  Oncostatin M and TLR-4 Ligand Synergize to Induce MCP-1, IL-6, and VEGF in Human Aortic Adventitial Fibroblasts and Smooth Muscle Cells , 2013, Mediators of inflammation.

[28]  J. H. Kim,et al.  Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and TGFBI. , 2013, The international journal of biochemistry & cell biology.

[29]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[30]  Xin Zhang,et al.  CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. , 2012, Cell stem cell.

[31]  O. Lee,et al.  Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect. , 2012, Cancer research.

[32]  O. Delattre,et al.  Oncostatin M is a growth factor for Ewing sarcoma. , 2012, The American journal of pathology.

[33]  S. Chevalier,et al.  Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling , 2012, Stem cells.

[34]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[35]  Ying Yue,et al.  Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3. , 2011, International journal of molecular medicine.

[36]  D. Heymann,et al.  Direct anti‐cancer effect of oncostatin M on chondrosarcoma , 2011, International journal of cancer.

[37]  Jonas Renström,et al.  How the niche regulates hematopoietic stem cells. , 2010, Chemico-biological interactions.

[38]  T. Martin,et al.  Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. , 2010, The Journal of clinical investigation.

[39]  L. Hennighausen,et al.  Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. , 2009, Blood.

[40]  K. Götze,et al.  Oncostatin M‐Mediated Regulation of KIT‐Ligand‐Induced Extracellular Signal‐Regulated Kinase Signaling Maintains Hematopoietic Repopulating Activity of Lin−CD34+CD133+ Cord Blood Cells , 2008, Stem cells.

[41]  M. Mansukhani,et al.  Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha , 2008, Molecular Cancer.

[42]  D. Smyth,et al.  Oncostatin M-Induced IL-6 Expression in Murine Fibroblasts Requires the Activation of Protein Kinase Cδ1 , 2006, The Journal of Immunology.

[43]  Y. Hirabayashi,et al.  Oncostatin M Maintains the Hematopoietic Microenvironment and Retains Hematopoietic Progenitors in the Bone Marrow , 2006, International journal of hematology.

[44]  J. Pfeilschifter,et al.  Oncostatin M expression is functionally connected to neutrophils in the early inflammatory phase of skin repair: implications for normal and diabetes-impaired wounds. , 2006, The Journal of investigative dermatology.

[45]  C. Keller-Peck,et al.  Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. , 2005, Cancer research.

[46]  D. Fuchs,et al.  Interleukin‐6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen‐activated protein kinase and phosphatidylinositol 3‐kinase , 2005, The Prostate.

[47]  M. Katsuki,et al.  Targeted disruption of oncostatin M receptor results in altered hematopoiesis. , 2003, Blood.

[48]  C. Miething,et al.  Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. , 2003, Blood.

[49]  K. Nilsson,et al.  Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells. , 2003, Blood.

[50]  R. DePinho,et al.  STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. , 2002, Immunity.

[51]  L. Naeger,et al.  Th1 cells regulate hematopoietic progenitor cell homeostasis by production of oncostatin M. , 2002, Immunity.

[52]  K. Chida,et al.  Oncostatin M production by human dendritic cells in response to bacterial products. , 2002, Cytokine.

[53]  M. Obinata,et al.  Oncostatin M regulates mesenchymal cell differentiation and enhances hematopoietic supportive activity of bone marrow stromal cell lines , 2001, In Vitro Cellular & Developmental Biology - Animal.

[54]  C. Nordborg,et al.  Expression of the IL-6 family cytokines in human brain tumors. , 2001, International journal of oncology.

[55]  Jingwen Liu,et al.  Oncostatin M–induced growth inhibition and morphological changes of MDA‐MB231 breast cancer cells are abolished by blocking the MEK/ERK signaling pathway , 2001, Breast Cancer Research and Treatment.

[56]  H. Halfter,et al.  Complete inhibition of in vivo glioma growth by oncostatin M , 2001, Journal of neurochemistry.

[57]  M. Dehoux,et al.  Oncostatin M Production by Blood and Alveolar Neutrophils during Acute Lung Injury , 2001, Laboratory Investigation.

[58]  P. Heinrich,et al.  Non-redundant Signal Transduction of Interleukin-6-type Cytokines , 2000, The Journal of Biological Chemistry.

[59]  M. Loh,et al.  Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. , 2000, Molecular cell.

[60]  A. Miyajima,et al.  Role of Oncostatin M in hematopoiesis and liver development. , 2000, Cytokine & growth factor reviews.

[61]  J. Tavernier,et al.  Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. , 1999, Journal of immunology.

[62]  B. Bonavida,et al.  Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. , 1999, Anticancer research.

[63]  A. Boutten,et al.  Oncostatin M production and regulation by human polymorphonuclear neutrophils. , 1999, Blood.

[64]  M. Ichihara,et al.  Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. , 1997, Blood.

[65]  C. Guillet,et al.  Signaling of Type II Oncostatin M Receptor* , 1997, The Journal of Biological Chemistry.

[66]  L. Hennighausen,et al.  Stat5a is mandatory for adult mammary gland development and lactogenesis. , 1997, Genes & development.

[67]  K. Pulkki,et al.  Serum oncostatin M in multiple myeloma: association with prognostic factors , 1997, British journal of haematology.

[68]  D. Friend,et al.  Dual Oncostatin M (OSM) Receptors , 1996, The Journal of Biological Chemistry.

[69]  J. Darnell,et al.  Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Xin-Yuan Fu,et al.  Cell Growth Arrest and Induction of Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Mediated by STAT1 , 1996, Science.

[71]  H. Haugen,et al.  Developmental abnormalities in mice transgenic for bovine oncostatin M , 1995, Molecular and cellular biology.

[72]  Comeau,et al.  The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. , 1992, Science.

[73]  J. Liu,et al.  Regulation of IL-6 expression by oncostatin M. , 1991, Journal of immunology.

[74]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.

[75]  H. Marquardt,et al.  Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. , 1987, Journal of immunology.

[76]  G. Todaro,et al.  Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[77]  A. Zorluoğlu,et al.  Oncostatin-M as a novel biomarker in colon cancer patients and its association with clinicopathologic variables. , 2014, European review for medical and pharmacological sciences.

[78]  J. Marrero,et al.  Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. , 2012, Cancer biomarkers : section A of Disease markers.

[79]  S. Jo,et al.  Oncostatin M induces growth arrest of skeletal muscle cells in G1 phase by regulating cyclin D1 protein level. , 2008, Cellular signalling.

[80]  P. Heinrich,et al.  Oncostatin M-induced activation of stress-activated MAP kinases depends on tyrosine 861 in the OSM receptor and requires Jak1 but not Src kinases. , 2006, Cellular signalling.

[81]  M. Błasińska-Morawiec,et al.  Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. , 1999, Mediators of inflammation.

[82]  J. Aster,et al.  Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. , 1998, Blood.

[83]  T. Hirano,et al.  Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily , 1994, Stem cells.

[84]  P. Linsley,et al.  Regulation of cell growth by recombinant oncostatin M. , 1990, Growth factors.